Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bionano GenomicsMEX:BNGO -0.45%61 PS Ratio is 0.23 as of Jul. 22, 2026, which is 89% below its 10-year median of 2.02. GuruFocus rates MEX:BNGO with a GF Score™ of 61/100 and a GF Value™ of MXN27.32 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 804 Medical Devices & Instruments companies, Bionano Genomics ranks better than 96.64% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Bionano Genomics's share price is MXN20.00.
Bionano Genomics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was MXN86.47. Hence, Bionano Genomics's PS Ratio for today is 0.23.
The historical rank and industry rank for Bionano Genomics's PS Ratio or its related term are showing as below:
MEX:BNGO'
s PS Ratio Range Over the Past 10 Years
Min: 0.11 Med: 2.02 Max: 166.03
Current: 0.24
During the past 10 years, Bionano Genomics's highest PS Ratio was 166.03. The lowest was 0.11. And the median was 2.02.
MEX:BNGO's PS Ratio is ranked better than 96.64% of 804
companies
in the Medical Devices & Instruments industry
Industry Median: 2.82
vs MEX:BNGO: 0.24
Bionano Genomics Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Bionano Genomics was -74.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -55.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -30.00% per year.
During the past 10 years, Bionano Genomics's highest 3-Year average Revenue per Share Growth Rate was 9.10% per year. The lowest was -70.50% per year. And the median was -47.80% per year.
Back to Basics: PS Ratio
Bionano Genomics (MEX:BNGO) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Bionano Genomics PS Ratio Related Terms
Bionano Genomics PS Ratio Historical Data
* Premium members only.
The historical data trend for Bionano Genomics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Bionano Genomics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionano Genomics PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bionano Genomics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Bionano Genomics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Bionano Genomics's Share Price of today is MXN20.00. Bionano Genomics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN86.47.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Bionano Genomics (MEX:BNGO) has a PS Ratio of 0.23 as of Jul. 22, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Bionano Genomics and its competitors. This is 89% below median its historical median of 2.02. Over the past decade, Bionano Genomics' PS Ratio has ranged from 0.11 to 166.03. According to the industry distribution chart, Bionano Genomics ranks #27 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 3.4%.
Is Bionano Genomics' PS Ratio too high?
Bionano Genomics' current PS Ratio of 0.23 is 89% below median its 10-year median of 2.02. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 166.03. The Medical Devices & Instruments industry median PS Ratio is 2.82. Bionano Genomics' value of 0.23 is 91.8% below this industry median. Based on the distribution chart, Bionano Genomics ranks #27 out of 804 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bionano Genomics has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bionano Genomics' PS Ratio compare to UEEC and CUPR?
According to the Medical Devices & Instruments industry distribution chart, Bionano Genomics ranks #27 out of 804 companies for PS Ratio. This places Bionano Genomics in the top 3% of its industry — outperforming the majority of peers. The industry median PS Ratio is 2.82. Bionano Genomics' value of 0.23 is 91.8% below this benchmark. Historically, Bionano Genomics' own PS Ratio has ranged from 0.11 to 166.03 over the past decade. While the company's 10-year median is 2.02 vs. the industry median of 2.82, Bionano Genomics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.82, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bionano Genomics's current PS Ratio of 0.23 is 91.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Bionano Genomics and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bionano Genomics's current PS Ratio is 0.23, which is 89% below median its own 10-year median of 2.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionano Genomics stock overvalued right now?
Based on GuruFocus' analysis, Bionano Genomics (MEX:BNGO) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN27.32, compared to a current price of MXN20.00 — trading 26.8% below its estimated fair value. The current PS Ratio is 0.23, which is 89% below median its 10-year median of 2.02 and 91.8% below the Medical Devices & Instruments industry median of 2.82. Bionano Genomics' overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Bionano Genomics (MEX:BNGO), the current PS Ratio is 0.23 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bionano Genomics (MEX:BNGO) Overvalued in 2026?
Based on GuruFocus' analysis, Bionano Genomics stock appears to be undervalued.
The current stock price of MXN20.00 is trading 26.8% below its estimated GF Value™ of MXN27.32.
GuruFocus considers Bionano Genomics to be Modestly Undervalued.
Key valuation signals for MEX:BNGO:
PS Ratio: 0.23 (89% below median its 10-year median of 2.02)
GF Value™: MXN27.32 vs. price of MXN20.00 (26.8% below fair value)
Industry Position: 91.8% below the Medical Devices & Instruments median (#27 of 804)
No single metric tells the full story. See the MEX:BNGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
61GF Score
Get the complete analysis for MEX:BNGO
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BNGO has been successfully added to your 
